Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
111.79
+1.28 (1.16%)
Sep 30, 2026, 4:00 PM EDT - Market closed
Kymera Therapeutics Stock Forecast
Stock Price Forecast
According to 23 analysts polled by S&P Global, Kymera Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $138.64. The average 1-year stock price forecast is 24.02% higher than the current stock price, while the lowest is $111 (-0.71%) and the highest is $180 (+61.02%).
Price Target: $138.64 (+24.02%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Kymera Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 18 | 17 | 17 | 17 | 17 |
| Buy | 5 | 5 | 5 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 23 | 24 | 23 | 24 | 24 | 23 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Buy Reiterates $140 | Buy | Reiterates | $140 | +25.23% | Sep 28, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $140 | Buy | Maintains | $140 | +25.23% | Sep 23, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $132 → $152 | Buy | Maintains | $132 → $152 | +35.97% | Sep 22, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $123 → $144 | Buy | Reiterates | $123 → $144 | +28.81% | Sep 14, 2026 |
| Wolfe Research | Wolfe Research | Buy Upgrades $180 | Buy | Upgrades | $180 | +61.02% | Sep 10, 2026 |
Financial Forecast
Revenue This Year
105.03M
from 39.21M
Increased by 167.86%
Revenue Next Year
40.21M
from 105.03M
Decreased by -61.72%
EPS This Year
-3.84
from -3.69
EPS Next Year
-5.10
from -3.84
EPS and Forward PE are based on non-GAAP adjusted numbers.